Background: There is still little data about long term results of unprotected left main stenting. In a multicenter randomized trial we compared percutaneous coronary intervention (PCI) using Sirolimus eluting stents to bypass revascularisation (CABG) for patients with significant left main stenosis. We present the cumulative 5-years results and therefore the longest available results of a randomized left main study at all. Methods: Between 8/2003 and 9/2008 a total of 201 pts with hemodynamically significant stenosis of the unprotected left main coronary artery were recruited in 4 german centers. The primary endpoint of the study was death, myocardial infarction, stroke and target vessel re-intervention. Hundred patients were randomized within the PCI-group and 101 patients within the CABG-group. There were no differences in the baseline characteristics. The left main lesion was located at the ostium in 22%, midshaft in 8% and at the bifurcation in 70%. Nearly half of the CABG patients were operated on using an off-pump technique (46%) and with total arterial revascularization in 65%. Complete revascularization was achieved in both groups. Results: Over a cumulative period of 5 years, 14 pts (14.1%) within the CABG group and 11 pts (11.1%) within the PCI group died. Myocardial infarction occurred in 2 patients after CABG and in 4 PCI patients after PCI. One patient had a stroke in the PCI group and 2 patients in the CABG group. The incidence of stroke was found to be low (1 vs 2 within the PCI and CABG group, respectively). Reintervention within the PCI group was required in 20 patients (3/20 underwent CABG) vs 9 patients within the CABG goup. Cumulative MACCE rate after 5 years was 36.4% for the PCI group vs 27.3% for the CABG group (p = 0.16 for non-inferiority).
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TCT-328
Long-term outcome after percutaneous coronary intervention with titaniumnitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a five-year follow-up of the TITAX-AMI trial Hospital, Oulu, Finland; 4 Turku University Hospital, Turku, Finland; 5 Kokkola Central Hospital, Kokkola, Finland; 6 Jyväskylä Central Hospital, Jyväskylä, Finland Background: The aim of this study was to evaluate the long-term safety and efficacy of the titanium-nitride-oxide-coated (TITANOX) stent and the paclitaxel-eluting stent (PES) in patients with acute myocardial infarction (MI) treated with a percutaneous coronary intervention (PCI). Methods: Altogether 425 patients presenting with acute non-ST-elevation MI or STelevation MI were randomly assigned to receive TITANOX stent or PES during PCI. The primary end point was a composite of MI, target lesion revascularization (TLR) or death from cardiac causes. Results: At 12 months, there was no significant difference between patients receiving TITANOX stent or PES in the rate of primary end point (10.3% vs. 12.8%, p=0.5), whereas a significantly lower rate of primary end-point was observed in the TITANOX stent group compared with the PES group (11.2% vs. 21.8%, p<0.01) after a two-year follow-up. After three years the rates of MI (6.1% vs. 16.6%, p<0.01), cardiac death (1.4% vs. 5.2%, p<0.05), MACE (13.1% vs. 23.7%, p<0.01) and definite stent thrombosis (ST) (0.5% vs. 6.6%, p<0.001) were significantly lower in the TITANOX arm compared with the PES arm. The five-year follow-up will be completed within a few months and the results will be presented in TCT 2011 congress if accepted.
Conclusion:
The implantation of a TITANOX stent had resulted in better clinical outcome compared with a PES during both two and three years of follow-up among patients treated for acute MI. The long-term outcome will be updated after a five-year follow-up. Background: Bivalirudin use during primary percutaneous coronary intervention (PCI) is nowadays a cornerstone for the management of ST elevation myocardial infarction (STEMI). However, an increased acute stent thrombosis rate has been found in patients treated with bivalirudin in the Horizons-AMI trial. A prolonged infusion after PCI has already been shown to be a safe and effective tool in patients undergoing complex urgent or elective PCI in the Probi Viri study. We examined the effects of a prolonged drug infusion after primary PCI. Methods: From the database of five high-volume italian centers, we compared a group of patients treated with a 4-hour prolonged bivalirudin infusion after PCI with two groups treated with a normal, peri-PCI infusion and heparin+abciximab for 12 hours. Primary study endpoint was >70% ST segment resolution (STR) within 90 minutes after PCI, secondary endpoints were partial (>50%) STR within 90 min and intrahospital TIMI major and minor bleedings. Results: Study population consisted of 264 patients undergoing primary PCI, all pretreated with aspirin and clopidogrel (600 mg). The three study groups did not differ significantly for baseline characteristics. Primary endpoint in prolonged bivalirudin, normal bivalirudin and heparin+abciximab groups was achieved respectively in 69.8%, 48.8% and 69.6% of patients (p between prolonged and standard infusion = 0.048, between prolonged infusion and abciximab =0.98). Major bleedings and other secondary study endpoints were not significantly different between the study groups. Conclusion: A strategy of prolonged bivalirudin infusion after primary PCI seems equivalent to a strategy with heparin+abciximab and better than a standard infusion in obtaining improved early microvascular reperfusion. Further studies with a bigger population are needed to clarify if this strategy exerts clinical benefits. A. Jain, C. Knight, A. Mathur, A. Wragg Cardiology, The London Chest Hospital, London, United Kingdom Background: Recent data suggests patients with coronary disease in large arteries are at increased risk of adverse events after PCI with first-generation drug-eluting stents (DES) as compared with bare-metal stents (BMS). We sought to investigate this observation in patients undergoing Primary PCI. Methods: 2447 consecutive patients undergoing Primary PCI for STEMI at a London centre between Oct 2003 and May 2010 were included. The primary end point used was major adverse cardiac events (MACE) defined as death, myocardial infarction (MI), stroke and target vessel revascularization (TVR). Results: Of the 2447 patients 933 required stents between 3 and 4mm in diameter, 809 were BMS and 124 DES. The DES group had higher rates of diabetes (22% vs 13% p = 0.01), previous MI (20% vs 12%, p = 0.02) and previous PCI (10% vs 5%, p=<0.04). There was a higher average number of stents used in the DES group (1.7 vs 1.5, p =0.03) and a higher average stent length in the DES group (19.12 vs 16.05, p=0.002). There was a significant difference in MACE between the two groups in favour of DES (12% BMS v 5% DES group [p = 0.04) at 3 years (figure 1). The rate of target-vessel revascularization was significantly reduced among patients receiving DES with TVR rates of 2.2% among patients receiving DES compared to 8.1% among those receiving BMS(p = 0.03). There were no significant differences in the rate of death, myocardial infarction, or stent thrombosis.
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